GlassScriptPhysician profile
James Bradley Ray
NPI 1871590943
$2,241.47
in general payments reported to CMS, 2019-2025
22 companies · $191 in 2025
The $191 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $356 · 2020: $282 · 2022: $406 · 2023: $432 · 2024: $574 · 2025: $191.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,197.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,196.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $760.96 | 2019-2024 | Echelon; Endopath, Surgicel Nu-Knit, Ethicon |
| Intra-Sana Laboratories | $264.00 | 2023-2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| W. L. Gore & Associates, INC. | $146.64 | 2022 | |
| Organogenesis INC. | $131.75 | 2022-2023 | Puraply |
| Davol INC. | $131.19 | 2025 | Arista |
| Takeda Pharmaceuticals U.S.A., INC. | $128.09 | 2022-2024 | Gattex |
| Arthrex, INC. | $102.26 | 2024 | Arthrex |
| Intuitive Surgical, INC. | $80.25 | 2023 | |
| Medical Device Business Services, INC. | $79.42 | 2020 | |
| Novo Nordisk INC | $73.25 | 2022-2025 | Wegovy |
| Medtronic, INC. | $60.33 | 2022-2024 | Progrip |
| Kvk-Tech, INC. | $53.80 | 2024 | |
| Ferring Pharmaceuticals INC. | $48.87 | 2022-2023 | Rebyota |
| Kowa Pharmaceuticals America, INC. | $34.72 | 2023 | Seglentis |
| Endogastric Solutions, INC | $27.82 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Immedica Pharma US, INC. | $19.54 | 2024 | |
| Ardelyx, INC. | $18.42 | 2023 | Ibsrela |
| Vertex Pharmaceuticals Incorporated | $17.44 | 2024 | |
| La Jolla Pharmaceutical Company | $17.40 | 2023 | Xerava |
| Braintree Laboratories, INC. | $15.68 | 2024 | Suflave, Sutab |
| Endo Pharmaceuticals INC. | $15.52 | 2019 | |
| Ambu INC. | $14.12 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Ray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.